Prenatal exposure to per- and polyfluoroalkyl substances, fetoplacental hemodynamics, and fetal growth
Por:
Knox, B, Güil-Oumrait, N, Basagaña, X, Cserbik, D, Dadvand, P, Foraster, M, Galmes, T, Gascon, M, Gomez-Roig, MD, Gomez-Herrera, L, Haug, LS, Llurba, E, Márquez, S, Rivas, I, Sunyer, J, Thomsen, C, Zanini, MJ, Bustamante, M, Vrijheid, M
Publicada:
1 nov 2024
Ahead of Print:
1 oct 2024
Resumen:
Introduction: The impact of legacy per- and polyfluoroalkyl substances (PFAS) on fetal growth has been well studied, but assessments of next-generation PFAS and PFAS mixtures are sparse and the potential role of fetoplacental hemodynamics has not been studied. We aimed to evaluate associations between prenatal PFAS exposure and fetal growth and fetoplacental hemodynamics. Methods: We included 747 pregnant women from the BiSC birth cohort (Barcelona, Spain (2018-2021)). Twentythree PFAS were measured at 32 weeks of pregnancy in maternal plasma, of which 13 were present above detectable levels. Fetal growth was measured by ultrasound, as estimated fetal weight at 32 and 37 weeks of gestation, and weight at birth. Doppler ultrasound measurements for uterine (UtA), umbilical (UmA), and middle cerebral artery (MCA) pulsatility indices (PI), as well as the cerebroplacental ratio (CPR - ratio MCA to UmA), were obtained at 32 weeks to assess fetoplacental hemodynamics. We applied linear mixed effects models to assess the association between singular PFAS and longitudinal fetal growth and PI, and Bayesian Weighted Quantile Sum models to evaluate associations between the PFAS mixture and the aforementioned outcomes, controlled for the relevant covariates. Results: Single PFAS and the mixture tended to be associated with reduced fetal growth and CPR PI, but few associations reached statistical significance. Legacy PFAS PFOS, PFHpA, and PFDoDa were associated with statistically significant decreases in fetal weight z-score of 0.13 (95%CI (-0.22,-0.04), 0.06 (-0.10, 0.01), and 0.05 (-0.10, 0.00), respectively, per doubling of concentration. The PFAS mixture was associated with a non- statistically significant 0.09 decrease in birth weight z-score (95%CI-0.22, 0.04) per quartile increase. Conclusion: This study suggests that legacy PFAS may be associated with reduced fetal growth, but associations for next generation PFAS and for the PFAS mixture were less conclusive. Associations between PFAS and fetoplacental hemodynamics warrant further investigation.
Filiaciones:
Knox, B:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Güil-Oumrait, N:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Icahn Sch Med Mt Sinai, Dept Environm Med & Publ Hlth, New York, NY USA
Basagaña, X:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Cserbik, D:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Dadvand, P:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Foraster, M:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Galmes, T:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Gascon, M:
Fdn Inst Univ Recerca Atencio Primaria Salut Jordi, Unitat Suport Recerca Catalunya Cent, Barcelona 08007, Spain
Gomez-Roig, MD:
Univ Barcelona, Hosp Sant Joan Deu & Hosp Clin, Fetal Med Res Ctr, Barcelona, Spain
Inst Salud Carlos III, Primary Care Intervent Prevent Maternal & Child Ch, RD21 0012 0003, Madrid, Spain
Inst Recerca Sant Joan Deu, Barcelona, Spain
Gomez-Herrera, L:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Haug, LS:
Norwegian Inst Publ Hlth NIPH, Oslo, Norway
Llurba, E:
Hosp Santa Creu i Sant Pau, Inst Invest Biomed Sant Pau IIB Sant Pau, Dept Obstet & Gynaecol, Barcelona 08025, Spain
Inst Salud Carlos III, Primary Care Intervent Prevent Maternal & Child Ch, RD21 0012 0001, Madrid 28029, Spain
Márquez, S:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Rivas, I:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Sunyer, J:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Thomsen, C:
Norwegian Inst Publ Hlth NIPH, Oslo, Norway
Zanini, MJ:
Univ Barcelona, Hosp Sant Joan Deu & Hosp Clin, Fetal Med Res Ctr, Barcelona, Spain
Inst Salud Carlos III, Primary Care Intervent Prevent Maternal & Child Ch, RD21 0012 0003, Madrid, Spain
Bustamante, M:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Vrijheid, M:
ISGlobal, Barcelona, Spain
Univ Pompeu Fabra UPF, Barcelona, Spain
Inst Salud Carlos III, Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
Barcelona Inst Global Hlth ISGlobal, 88 Dr Aiguader, Barcelona, Spain
gold
|